What is it about?
Cancer is undoubtedly a major challenge of modern era and is the second leading cause of death in the world. Lung cancer is the second most common cancer and the leading cause of cancer death among men and women. Non-Small Cell Lung Cancer (NSCLC) account for 84% of all lung cancer diagnosed. The present research focused on incorporating pyrazoline nucleus into benzimidazole nucleus to form a potent anticancer agent targeting lung cancer therapy.
Photo by CDC on Unsplash
Why is it important?
The in silico novel pyrazoline substituted benzimidazole derivatives were designed. Docking was performed to know the binding interactions of the newer agents with the enzymes. The compounds which were found to be active in docking studies were synthesized and tested for anticancer activity. In vitro screening of the selected derivatives for anticancer activity by MTT assay method showed very good results. Cytotoxicity of compounds BZ1, BZ2, BZ10 and BZ16 studied against fibrosarcoma and lung cancer cell line
Read the Original
This page is a summary of: Design, Synthesis and Pharmacological Evaluation of Novel Benzimidazole Derivatives as Anticancer Agents, Current Bioactive Compounds, July 2022, Bentham Science Publishers, DOI: 10.2174/1573407217666210813144009.
You can read the full text:
The following have contributed to this page